KURA - Kura Oncology's Head & Neck Cancer Candidate Shows Meaningful Antitumor Activity In Pretreated Patients | Benzinga
Kura Oncology Inc (NASDAQ: KURA) announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is recurrent or metastatic (R/M) and has progressed after prior therapy.
These clinical results will be featured during a late-breaking oral session at the 2023 European Society for Medical Oncology (ESMO) Congress.
As of the data cutoff on June 15, 2023, 59 patients with R/M HRAS mutant ...